Roche Tecentriq Phase III Combo Study Meets Primary Endpoint
Zacks Investment Research | Mar 20, 2018 05:01AM ET
Roche Holding (SIX:ROG) AG’s (OTC:RHHBY) subsidiary Genentech announced that a phase III study, evaluating a combination of its PD-L1 inhibitor Tecentriqplus chemotherapy (carboplatin and Abraxane) for first line treatment of advanced lung cancer met its co-primary endpoint of progression-free survival (“PFS”). The IMpower131 study showed that the combination reduced the risk of disease worsening or death (PFS) compared with chemotherapy alone in the initial treatment of patients with advanced squamous non-small cell lung cancer (“NSCLC”).
However, the above results did not show a statistically significant overall survival (“OS”) benefit. Hence the study will be continued. and the interim data will be presented at an upcoming oncology congress.
Over a year, shares of Roche have declined 8.2% against the industry ’s growth of 8.1%.
Tecentriq is marketed for the treatment of second-line metastatic NSCLC. Label expansion in the first line setting should boost the drug’s sales further. Tecentriq is also approved for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin chemotherapy. The drug recored sales of CHF457 million in 2017.
In February 2018, Roche announced positive results from the phase III IMmotion151 study on Tecentriq in combination with oncology drug Avastin (bevacizumab) as a first line treatment for advanced or metastatic renal cell carcinoma. The study met its co-primary endpoint of investigator-assessed PFS in patients whose disease expressed the PD-L1 protein. Results showed that patients who received Tecentriq plus Avastin had a 26% reduced risk of disease worsening or death (PFS) compared to people treated with Sutent.
We remind investors that Merck’s (NYSE:MRK) PD-L1 inhibitor Keytruda is approved by the FDA both as monotherapy and in combination with Lilly’s (NYSE:LLY) Alimta and carboplatin for the first line treatment of patients with metastatic nonsquamous NSCLC.
Zacks Rank & Another Stock to Consider
Roche carries a Zacks Rank #2 (Buy).
Another top-ranked stock from the same space is Regeneron Pharmaceuticals (NASDAQ:REGN) ,sporting a Zacks Rank #1 (Strong Buy). You can see .
Get The News You Want
Regeneron’s earnings per share estimates have moved up from $18.65 to $18.68 for 2018 in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, with an average beat of 9.15%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2%, respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.